Man Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Man Guo has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- Yong Xu
Department of Endocrinology and Metabolism, The Affiliated Hospital of Southwest Medical University, Luzhou, China
16 shared publications - Fang-Yuan Teng
Department of Endocrinology and Metabolism, The Affiliated Hospital of Southwest Medical University, Luzhou, China
8 shared publications - Yang Long
Department of Endocrinology and Metabolism, The Affiliated Hospital of Southwest Medical University, Luzhou, China
7 shared publications Qi Wu
Department of Endocrinology and Metabolism, The Affiliated Hospital of Southwest Medical University, Luzhou, China
5 shared publications- Fan Feng
Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi’an, China
4 shared publications - Hongwei Zhang
Xijing Hospital of Digestive Diseases, Xijing Hospital of Digestive Diseases, Fourth Military Medical University
4 shared publications
Latest Publications
- 15 August 2026
- Published by Springer Nature in Endocrine
- Vol. 91 (1) , 275
Effect of tirzepatide and semaglutide on blood pressure: A systematic review and meta-analysis
- 15 August 2026
- Published by Springer Nature in Endocrine
- Vol. 91 (1) , 275
Effect of tirzepatide and semaglutide on blood pressure: A systematic review and meta-analysis
- Open Access
- 18 June 2026
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 18 (1)
Cardiovascular outcomes of semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis
To systematically evaluate cardiovascular outcomes associated with semaglutide and tirzepatide in adults with type 2 diabetes mellitus (T2DM), overweight o
- 18 June 2026
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 18 (1)
Open AccessCardiovascular outcomes of semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis
To systematically evaluate cardiovascular outcomes associated with semaglutide and tirzepatide in adults with type 2 diabetes mellitus (T2DM), overweight o
- 11 February 2026
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 42 (2) , e70134
Association Between GLP‐1 Receptor Agonists and the Risk of Colon Cancer in Adults With Type 2 Diabetes or Obesity: A Systematic Review and Network Meta‐Analysis
Background and Objective: To evaluate the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and intestinal cancers and to explore the risk factors for these associations. Methods: PubMed, Embase, Web of Science, Scopus, Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials.gov were searched through 13 June 2024, to identify randomised clinical trials (RCTs) assessing the relationship between GLP‐1 RA use and colorectal, colon, rectal, and intestinal cancers. Pooled relative risks (RRs) and 95% confidence intervals (CIs) for each outcome were calculated. Results: In 17 RCTs comprising 36,415 patients, GLP‐1 RAs was associated with a significantly reduced risk of colon cancer (RR, 0.34; 95% CI, 0.17–0.68; I 2 = 0.0%), and showed a neutral effect on the risk of colorectal carcinoma, rectal, and intestinal cancer, with RRs of 1.13 (95% CI, 0.92–1.39; I 2 = 0.0%), 3.64 (95% CI, 0.76–17.40; I 2 = 0.0%), and 0.76 (95% CI, 0.31–1.84; I 2 = 23.3%), respectively. In the network meta‐analysis and subgroup analysis, a potential association was observed between albiglutide and subcutaneous semaglutide and a lower incidence of colon cancer among adults treated for a longer duration and with lower baseline HbA1c levels, regardless of baseline body mass index, age, or type of control group. Conclusions: GLP‐1 RAs may be associated with a lower risk of colon cancer in adults with type 2 diabetes mellitus, warranting further validation in trials among high‐risk populations. Trial Registration: The study protocol was pre‐registered and published on PROSPERO (CRD: 42024548010; https://www.crd.york.ac.uk/prospero/#recordDetails )
- 11 February 2026
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 42 (2) , e70134
Association Between GLP‐1 Receptor Agonists and the Risk of Colon Cancer in Adults With Type 2 Diabetes or Obesity: A Systematic Review and Network Meta‐Analysis
Background and Objective: To evaluate the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and intestinal cancers and to explore the risk factors for these associations. Methods: PubMed, Embase, Web of Science, Scopus, Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials.gov were searched through 13 June 2024, to identify randomised clinical trials (RCTs) assessing the relationship between GLP‐1 RA use and colorectal, colon, rectal, and intestinal cancers. Pooled relative risks (RRs) and 95% confidence intervals (CIs) for each outcome were calculated. Results: In 17 RCTs comprising 36,415 patients, GLP‐1 RAs was associated with a significantly reduced risk of colon cancer (RR, 0.34; 95% CI, 0.17–0.68; I 2 = 0.0%), and showed a neutral effect on the risk of colorectal carcinoma, rectal, and intestinal cancer, with RRs of 1.13 (95% CI, 0.92–1.39; I 2 = 0.0%), 3.64 (95% CI, 0.76–17.40; I 2 = 0.0%), and 0.76 (95% CI, 0.31–1.84; I 2 = 23.3%), respectively. In the network meta‐analysis and subgroup analysis, a potential association was observed between albiglutide and subcutaneous semaglutide and a lower incidence of colon cancer among adults treated for a longer duration and with lower baseline HbA1c levels, regardless of baseline body mass index, age, or type of control group. Conclusions: GLP‐1 RAs may be associated with a lower risk of colon cancer in adults with type 2 diabetes mellitus, warranting further validation in trials among high‐risk populations. Trial Registration: The study protocol was pre‐registered and published on PROSPERO (CRD: 42024548010; https://www.crd.york.ac.uk/prospero/#recordDetails )
- Open Access
- 1 January 2026
- Published by Wiley in Mediators of Inflammation
- Vol. 2026 (1)
Imidazole Propionate Induces Kidney Damage by Activating the ROS‐NLRP3 Signaling Pathway Through mTOR Inhibition of Autophagy in Renal Tubular Epithelial Cells
L‐Histidine, a parent structure of environmental contaminants (e.g., pesticides and preservatives), may undergo bioaccumulation through the food chain and be metabolized by the gut microbiota into deleterious compounds, ultimately compromising human health. Recent studies have identified abnormally elevated levels of the histidine‐derived metabolite imidazole propionate (ImP) in the serum of type 2 diabetes mellitus patients. However, the pathophysiological implications of excessive ImP on renal function and its underlying molecular mechanisms remain poorly characterized. This study is the first to elucidate the detrimental effects of ImP on renal function in mice and its molecular mechanisms. Our findings demonstrate that ImP exacerbates renal dysfunction and induces structural and functional abnormalities in renal tubules. Mechanistically, ImP significantly suppresses autophagy in renal tubular epithelial cells and activates the reactive oxygen species (ROS)‐NOD‐like receptor pyrin domain‐containing 3 (NLRP3) signaling pathway, thereby promoting the expression of the pro‐inflammatory cytokine interleukin‐1β (IL‐1β). Notably, the mechanistic target of rapamycin (mTOR) inhibitor rapamycin (Rap) restores autophagy, inhibits the ROS/NLRP3/IL‐1β axis, and mitigates ImP‐induced renal injury. Transcriptomic sequencing of mouse kidneys reveals that ImP upregulates the expression of autophagy‐ and inflammation‐related genes, while its inhibitor suppresses these genetic alterations. This study highlights the potential nephrotoxic effects of ImP and underscores the therapeutic value of Rap, providing a theoretical foundation for understanding the role of gut microbiota metabolites in the pathogenesis, prevention, and treatment of kidney diseases.
- 1 January 2026
- Published by Wiley in Mediators of Inflammation
- Vol. 2026 (1)
Open AccessImidazole Propionate Induces Kidney Damage by Activating the ROS‐NLRP3 Signaling Pathway Through mTOR Inhibition of Autophagy in Renal Tubular Epithelial Cells
L‐Histidine, a parent structure of environmental contaminants (e.g., pesticides and preservatives), may undergo bioaccumulation through the food chain and be metabolized by the gut microbiota into deleterious compounds, ultimately compromising human health. Recent studies have identified abnormally elevated levels of the histidine‐derived metabolite imidazole propionate (ImP) in the serum of type 2 diabetes mellitus patients. However, the pathophysiological implications of excessive ImP on renal function and its underlying molecular mechanisms remain poorly characterized. This study is the first to elucidate the detrimental effects of ImP on renal function in mice and its molecular mechanisms. Our findings demonstrate that ImP exacerbates renal dysfunction and induces structural and functional abnormalities in renal tubules. Mechanistically, ImP significantly suppresses autophagy in renal tubular epithelial cells and activates the reactive oxygen species (ROS)‐NOD‐like receptor pyrin domain‐containing 3 (NLRP3) signaling pathway, thereby promoting the expression of the pro‐inflammatory cytokine interleukin‐1β (IL‐1β). Notably, the mechanistic target of rapamycin (mTOR) inhibitor rapamycin (Rap) restores autophagy, inhibits the ROS/NLRP3/IL‐1β axis, and mitigates ImP‐induced renal injury. Transcriptomic sequencing of mouse kidneys reveals that ImP upregulates the expression of autophagy‐ and inflammation‐related genes, while its inhibitor suppresses these genetic alterations. This study highlights the potential nephrotoxic effects of ImP and underscores the therapeutic value of Rap, providing a theoretical foundation for understanding the role of gut microbiota metabolites in the pathogenesis, prevention, and treatment of kidney diseases.
- 16 October 2025
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 41 (7) , e70097
Effect of Tirzepatide on Heart Failure in Type 2 Diabetes Mellitus and Obesity: A Systematic Review and Meta‐Analysis
Aims: This systematic review and meta‐analysis aimed to evaluate the effects of tirzepatide on heart failure in patients with type 2 diabetes mellitus (T2DM) and obesity. Materials and Methods: An updated systematic search of the PubMed, Embase, The Cochrane Central Register of Controlled Trials, Scopus, Web of Science, and ClinicalTrials.gov databases for relevant studies, published from database inception to February 13, 2025, was performed using tirzepatide and heart failure‐related search terms. Results: Eleven randomized controlled trials (RCTs) (funded by Eli Lilly and Co., Indianapolis, IN, USA) comprising 13,378 participants were included. Compared with placebo or other active glucose‐lowering drugs, tirzepatide had a neutral effect on the overall risk for heart failure (risk ratio [RR] 0.63 [95% confidence interval (CI) 0.35–1.13]), but the effect was neither statistically nor clinically meaningful (absolute risk reduction [ARR] 0.17%, number needed to treat [NNT] 588; Food and Drug Administration (FDA) minimal important difference [MID] 1.5%). The certainty of evidence was rated as moderate according to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) criteria ( p = 0.628; I 2 = 0.0%). Subgroup analysis revealed different pooled estimates for heart failure outcomes in the ≤ 58 years of age subgroup (RR 0.40 [95% CI 0.17–0.96]) compared with the > 58 years' subgroup (RR 0.86 [95% CI 0.39–1.90]) ( p for interaction = 0.201). Additionally, subgroup analysis comparing tirzepatide alone with tirzepatide in combination with other agents revealed different pooled estimates ( p = 0.661; I 2 = 0.0%), with an RR 0.43 (95% CI 0.20–0.88) and 2.25 (95% CI 0.51–9.87), respectively ( p for interaction = 0.05). Subgroup analyses stratified according to different doses of tirzepatide, baseline body weight, body mass index, fasting plasma glucose, glycated haemoglobin, T2DM, obesity, or overweight, and intervention time indicated no association between tirzepatide use and the risk for heart failure. Conclusions: Tirzepatide had no overall effect on heart failure outcomes in patients with T2DM or obesity. However, among patients ≤ 58 years of age, tirzepatide yielded a 60% relative risk reduction (i.e., RR = 0.40), while in patients undergoing monotherapy, it yielded a 57% relative risk reduction (i.e., RR = 0.43). Results of this systematic review and meta‐analysis of RCTs support the safety of tirzepatide as a therapeutic option for the clinical management of T2DM or obesity. Trial Registration: PROSPERO registration number, CRD42024620051
- 16 October 2025
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 41 (7) , e70097
Effect of Tirzepatide on Heart Failure in Type 2 Diabetes Mellitus and Obesity: A Systematic Review and Meta‐Analysis
Aims: This systematic review and meta‐analysis aimed to evaluate the effects of tirzepatide on heart failure in patients with type 2 diabetes mellitus (T2DM) and obesity. Materials and Methods: An updated systematic search of the PubMed, Embase, The Cochrane Central Register of Controlled Trials, Scopus, Web of Science, and ClinicalTrials.gov databases for relevant studies, published from database inception to February 13, 2025, was performed using tirzepatide and heart failure‐related search terms. Results: Eleven randomized controlled trials (RCTs) (funded by Eli Lilly and Co., Indianapolis, IN, USA) comprising 13,378 participants were included. Compared with placebo or other active glucose‐lowering drugs, tirzepatide had a neutral effect on the overall risk for heart failure (risk ratio [RR] 0.63 [95% confidence interval (CI) 0.35–1.13]), but the effect was neither statistically nor clinically meaningful (absolute risk reduction [ARR] 0.17%, number needed to treat [NNT] 588; Food and Drug Administration (FDA) minimal important difference [MID] 1.5%). The certainty of evidence was rated as moderate according to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) criteria ( p = 0.628; I 2 = 0.0%). Subgroup analysis revealed different pooled estimates for heart failure outcomes in the ≤ 58 years of age subgroup (RR 0.40 [95% CI 0.17–0.96]) compared with the > 58 years' subgroup (RR 0.86 [95% CI 0.39–1.90]) ( p for interaction = 0.201). Additionally, subgroup analysis comparing tirzepatide alone with tirzepatide in combination with other agents revealed different pooled estimates ( p = 0.661; I 2 = 0.0%), with an RR 0.43 (95% CI 0.20–0.88) and 2.25 (95% CI 0.51–9.87), respectively ( p for interaction = 0.05). Subgroup analyses stratified according to different doses of tirzepatide, baseline body weight, body mass index, fasting plasma glucose, glycated haemoglobin, T2DM, obesity, or overweight, and intervention time indicated no association between tirzepatide use and the risk for heart failure. Conclusions: Tirzepatide had no overall effect on heart failure outcomes in patients with T2DM or obesity. However, among patients ≤ 58 years of age, tirzepatide yielded a 60% relative risk reduction (i.e., RR = 0.40), while in patients undergoing monotherapy, it yielded a 57% relative risk reduction (i.e., RR = 0.43). Results of this systematic review and meta‐analysis of RCTs support the safety of tirzepatide as a therapeutic option for the clinical management of T2DM or obesity. Trial Registration: PROSPERO registration number, CRD42024620051
- Open Access
- 20 March 2025
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 16, 1532587
A meta-analysis on the risk of esophageal cancer in type 2 diabetes patients treated with GLP-1 receptor agonists
Objective: To evaluate the association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) treatment and the risk of esophageal cancer in adults with type 2 diabetes mellitus (T2DM) or obesity through a comprehensive meta-analysis.Methods: A systematic computerized searches and collection of eligible randomized controlled trials (RCTs) was performed to compare the risk of esophageal cancer between GLP-1 RA and control agents. The bias risks and quality of the studies were evaluated, and a meta-analysis was conducted using Stata 18.0 and R 4.0.2 statistical software.Results: The meta-analysis included data from six studies involving 13,391 participants. The pooled relative risk (RR) of esophageal cancer in patients using GLP-1 RAs compared to control agents was 0.46 (95% CI 0.13-1.59; p=0.725; I²=0%). Subgroup analyses stratified by age groups, intervention durations, BMI categories, and indications for T2DM or obesity treatment more often indicated no association between GLP-1 RAs use and increased risk of esophageal cancer.Conclusions: GLP-1 RAs did not increase the incidence of esophageal neoplasms, and there were not probably significant within-class differences in T2DM or obesity treatment. This finding supports the safety of GLP-1 RAs as a therapeutic option for the clinical management of T2DM.Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42024543945.
- 20 March 2025
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 16, 1532587
Open AccessA meta-analysis on the risk of esophageal cancer in type 2 diabetes patients treated with GLP-1 receptor agonists
Objective: To evaluate the association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) treatment and the risk of esophageal cancer in adults with type 2 diabetes mellitus (T2DM) or obesity through a comprehensive meta-analysis.Methods: A systematic computerized searches and collection of eligible randomized controlled trials (RCTs) was performed to compare the risk of esophageal cancer between GLP-1 RA and control agents. The bias risks and quality of the studies were evaluated, and a meta-analysis was conducted using Stata 18.0 and R 4.0.2 statistical software.Results: The meta-analysis included data from six studies involving 13,391 participants. The pooled relative risk (RR) of esophageal cancer in patients using GLP-1 RAs compared to control agents was 0.46 (95% CI 0.13-1.59; p=0.725; I²=0%). Subgroup analyses stratified by age groups, intervention durations, BMI categories, and indications for T2DM or obesity treatment more often indicated no association between GLP-1 RAs use and increased risk of esophageal cancer.Conclusions: GLP-1 RAs did not increase the incidence of esophageal neoplasms, and there were not probably significant within-class differences in T2DM or obesity treatment. This finding supports the safety of GLP-1 RAs as a therapeutic option for the clinical management of T2DM.Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42024543945.
- Open Access
- 1 March 2024
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 17, 1051-1068
Development of Serum Lactate Level-Based Nomograms for Predicting Diabetic Kidney Disease in Type 2 Diabetes Mellitus Patients
Purpose: To establish nomograms integrating serum lactate levels and traditional risk factors for predicting diabetic kidney disease (DKD) in type 2 diabetes mellitus (T2DM) patients. Patients and methods: A total of 570 T2DM patients and 100 healthy subjects were enrolled. T2DM patients were categorized into normal and high lactate groups. Univariate and multivariate logistic regression analyses were employed to identify independent predictors for DKD. Then, nomograms for predicting DKD were established, and the model performance was evaluated using the area under the receiver operating characteristic curve (AUC), calibration, and decision curve analysis (DCA). Results: T2DM patients exhibited higher lactate levels compared to those in healthy subjects. Glucose, platelet, uric acid, creatinine, and hypertension were independent factors for DKD in T2DM patients with normal lactate levels, while diabetes duration, creatinine, total cholesterol, and hypertension were indicators in high lactate levels group (P< 0.05). The AUC values were 0.834 (95% CI, 0.776 to 0.891) and 0.741 (95% CI, 0.688 to 0.795) for nomograms in both normal lactate and high lactate groups, respectively. The calibration curve demonstrated excellent agreement of fit. Furthermore, the DCA revealed that the threshold probability and highest Net Yield were 17– 99% and 0.36, and 24– 99% and 0.24 for the models in normal lactate and high lactate groups, respectively. Conclusion: The serum lactate level-based nomogram models, combined with traditional risk factors, offer an effective tool for predicting DKD probability in T2DM patients. This approach holds promise for early risk assessment and tailored intervention strategies.
- 1 March 2024
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 17, 1051-1068
Open AccessDevelopment of Serum Lactate Level-Based Nomograms for Predicting Diabetic Kidney Disease in Type 2 Diabetes Mellitus Patients
Purpose: To establish nomograms integrating serum lactate levels and traditional risk factors for predicting diabetic kidney disease (DKD) in type 2 diabetes mellitus (T2DM) patients. Patients and methods: A total of 570 T2DM patients and 100 healthy subjects were enrolled. T2DM patients were categorized into normal and high lactate groups. Univariate and multivariate logistic regression analyses were employed to identify independent predictors for DKD. Then, nomograms for predicting DKD were established, and the model performance was evaluated using the area under the receiver operating characteristic curve (AUC), calibration, and decision curve analysis (DCA). Results: T2DM patients exhibited higher lactate levels compared to those in healthy subjects. Glucose, platelet, uric acid, creatinine, and hypertension were independent factors for DKD in T2DM patients with normal lactate levels, while diabetes duration, creatinine, total cholesterol, and hypertension were indicators in high lactate levels group (P< 0.05). The AUC values were 0.834 (95% CI, 0.776 to 0.891) and 0.741 (95% CI, 0.688 to 0.795) for nomograms in both normal lactate and high lactate groups, respectively. The calibration curve demonstrated excellent agreement of fit. Furthermore, the DCA revealed that the threshold probability and highest Net Yield were 17– 99% and 0.36, and 24– 99% and 0.24 for the models in normal lactate and high lactate groups, respectively. Conclusion: The serum lactate level-based nomogram models, combined with traditional risk factors, offer an effective tool for predicting DKD probability in T2DM patients. This approach holds promise for early risk assessment and tailored intervention strategies.
- Open Access
- 28 April 2023
- Published by Elsevier in Advances in Nutrition
- Vol. 14 (4) , 629-636
Effect of Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Outcomes in Patients with Diabetes: A Meta-analysis of Randomized Controlled Trials
- 28 April 2023
- Published by Elsevier in Advances in Nutrition
- Vol. 14 (4) , 629-636
Open AccessEffect of Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Outcomes in Patients with Diabetes: A Meta-analysis of Randomized Controlled Trials
- Open Access
- 30 January 2023
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2023, 1-14
High Glucose-Induced Kidney Injury via Activation of Necroptosis in Diabetic Kidney Disease
Diabetic kidney disease (DKD) is a major microvascular complication of diabetes mellitus (DM) and is closely associated to programmed cell death. However, the complex mechanisms of necroptosis, an alternative cell death pathway, in DKD pathogenesis are yet to be elucidated. This study indicates that necroptosis is involved in DKD induced by high glucose (HG) both in vivo and in vitro. HG intervention led to the activation of RIPK1/RIPK3/MLKL signaling, resulting in renal tissue necroptosis and proinflammatory activation in streptozotocin/high-fat diet- (STZ/HFD-) induced diabetic mice and HG-induced normal rat kidney tubular cells (NRK-52E). We further found that in HG-induced NRK-52E cell, necroptosis might, at least partly, depend on the levels of reactive oxygen species (ROS). Meanwhile, ROS participated in necroptosis via a positive feedback loop involving the RIPK1/RIPK3 pathway. In addition, blocking RIPK1/RIPK3/MLKL signaling by necrostatin-1 (Nec-1), a key inhibitor of RIPK1 in the necroptosis pathway, or antioxidant N-acetylcysteine (NAC), an inhibitor of ROS generation, could effectively protect the kidney against HG-induced damage, decrease the release of proinflammatory cytokines, and rescue renal function in STZ/HFD-induced diabetic mice. Inhibition of RIPK1 effectively decreased the activation of RIPK1-kinase-/NF-κB-dependent inflammation. Collectively, we demonstrated that high glucose induced DKD via renal tubular epithelium necroptosis, and Nec-1 or NAC treatment downregulated the RIPK1/RIPK3/MLKL pathway and finally reduced necroptosis, oxidative stress, and inflammation. Thus, RIPK1 may be a therapeutic target for DKD.
- 30 January 2023
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2023, 1-14
Open AccessHigh Glucose-Induced Kidney Injury via Activation of Necroptosis in Diabetic Kidney Disease
Diabetic kidney disease (DKD) is a major microvascular complication of diabetes mellitus (DM) and is closely associated to programmed cell death. However, the complex mechanisms of necroptosis, an alternative cell death pathway, in DKD pathogenesis are yet to be elucidated. This study indicates that necroptosis is involved in DKD induced by high glucose (HG) both in vivo and in vitro. HG intervention led to the activation of RIPK1/RIPK3/MLKL signaling, resulting in renal tissue necroptosis and proinflammatory activation in streptozotocin/high-fat diet- (STZ/HFD-) induced diabetic mice and HG-induced normal rat kidney tubular cells (NRK-52E). We further found that in HG-induced NRK-52E cell, necroptosis might, at least partly, depend on the levels of reactive oxygen species (ROS). Meanwhile, ROS participated in necroptosis via a positive feedback loop involving the RIPK1/RIPK3 pathway. In addition, blocking RIPK1/RIPK3/MLKL signaling by necrostatin-1 (Nec-1), a key inhibitor of RIPK1 in the necroptosis pathway, or antioxidant N-acetylcysteine (NAC), an inhibitor of ROS generation, could effectively protect the kidney against HG-induced damage, decrease the release of proinflammatory cytokines, and rescue renal function in STZ/HFD-induced diabetic mice. Inhibition of RIPK1 effectively decreased the activation of RIPK1-kinase-/NF-κB-dependent inflammation. Collectively, we demonstrated that high glucose induced DKD via renal tubular epithelium necroptosis, and Nec-1 or NAC treatment downregulated the RIPK1/RIPK3/MLKL pathway and finally reduced necroptosis, oxidative stress, and inflammation. Thus, RIPK1 may be a therapeutic target for DKD.